Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa

Authors:
  • CKCissy Kityo
    Cissy Kityo
  • AHAnne Hoppe
    Anne Hoppe
  • ARAndrew Reid
    Andrew Reid
  • AKAndrew Kambugu
    Andrew Kambugu
  • ALAbbas Lugemwa
    Abbas Lugemwa
  • JOJoep J. van Oosterhout
    Joep J. van Oosterhout
  • MKMary Kiconco
    Mary Kiconco
  • ASAbraham Siika
    Abraham Siika
  • RMRaymond Mwebaze
    Raymond Mwebaze
  • MAMary Abwola
    Mary Abwola

Abstract
The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing them with raltegravir may provide a benefit.

This publication has 24 references indexed in Scilit: